Isolation and identification of cyclic imide and deamidation products in heat stressed pramlintide injection drug product

This report summarizes the identification of six cyclic imide [Asu] and two deamidation products from a sample of pramlintide final drug product that had been stressed at 40 degrees C for 45 days. The pramlintide degradation products were isolated by cation exchange high-performance liquid chromatog raphy (HPLC) followed by reversed-phase HPLC. The isolated components were characterized by mass spectrometry (MS), tandem MS (MS/MS) and when necessa ry, by enzymatic (thermolysin) digestion followed by liquid chromatography/ mass spectrometry (LC/MS) and sequence analysis. The isolated products were identified as [Asu(14)]-pramlintide, [Asu(21)]-pramlintide, [Asu(22)]-pram lintide, [Asu(35)]-pramlintide, [1-21]-succinimide-pramlintide, and [1-22]- succinimide-pramlintide. Also identified were [Asp(35)]-pramlintide, the de amidation product of pramlintide at Asn(35), and [Tyr(37)-OH]-pramlintide, the deamidation product of the pramlintide amidated C-terminal Tyr. Togethe r these data support those presented earlier (C. Hekman et al., Isolation a nd identification of peptide degradation products of heat stressed pramlint ide injection drug product. Pharm Res 1998;15:650-9) indicating that the pr imary mechanism of degradation for pramlintide in this pH 4.0 formulation i s deamidation, with six of the eight possible deamidation sites observed to undergo deamidation. Gln-10 and Asn-31 are the only two residues subject t o deamidation for which none is observed. The data indicate that the cyclic imide products account for approximate to 20% of the total thermal degrada tion while the deamidation products account for approximate to 64%. The rem aining degradation is due to peptide backbone hydrolysis. (C) 1999 Elsevier Science B.V. All rights reserved.